289.00
+16(+5.86%)
Currency In JPY
Sector
Healthcare
Industry
Biotechnology
Employees
44
First IPO Date
August 09, 2019
| Name | Title | Pay | Year Born |
| Masatsune Okajima | President, Chief Executive Officer & Representative Director | 30M | 1968 |
| Katsuto Tamai | Founder, Chief Scientific Officer & Director | 0 | 1960 |
| Takehiko Yamazaki | Executive Officer, Head of Seeds Exploration Dept., Pharma. Research Dept. & Intellectual Property Dept. | 0 | 1970 |
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.